Iloprost Zentiva (Iloprost)

Iloprost mimics the natural prostacyclin molecule and activates prostacyclin (IP) receptors on pulmonary vascular smooth‑muscle cells. This activation raises intracellular cyclic AMP, causing smooth‑muscle relaxation (vasodilation) and inhibiting platelet aggregation, which together reduce pulmonary vascular resistance.

The prescribed dose of Iloprost Zentiva is individualized by the treating physician based on the patient’s clinical condition, response, and tolerability. The prescriber determines the number of inhalations, concentration, and frequency according to current clinical guidelines and patient needs.

Safety data for Iloprost during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing women.

To request Iloprost Zentiva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Iloprost belongs to the prostacyclin analogue class, similar to epoprostenol and treprostinil. Compared with epoprostenol, which is administered intravenously, Iloprost offers the convenience of inhalation, allowing targeted pulmonary delivery and potentially fewer systemic side effects. Treprostinil can be given by inhalation, subcutaneous or intravenous routes, providing more flexibility but also differing safety profiles.

Iloprost Zentiva should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from moisture and direct light. Do not freeze the product. Once opened, follow the manufacturer’s instructions regarding the stability period and discard any unused solution after the recommended time.

Iloprost Zentiva is administered via inhalation using a calibrated nebulizer device. The patient inhales the prescribed dose, typically multiple times per day, as directed by the healthcare provider. Proper training on the nebulizer technique is essential to ensure consistent drug delivery to the lungs.

The most serious adverse events associated with Iloprost include severe hypotension, pulmonary edema, and significant thrombocytopenia. Patients should be monitored for sudden drops in blood pressure, shortness of breath, fluid accumulation in the lungs, or unexpected bruising and bleeding, and any such symptoms should prompt immediate medical evaluation.

Iloprost Zentiva is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation. It should also be avoided in individuals with active severe bleeding, uncontrolled hypotension, or severe pulmonary edema. Caution is advised in patients with significant liver impairment or those taking other potent vasodilators.